267 related articles for article (PubMed ID: 20106600)
1. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
2. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
3. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
4. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
Ryan CJ; Lin AM; Small EJ
Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
7. [Targeted therapies for hormone-refractory prostate cancer].
Song HZ; Chen LB
Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
9. Management of prostate cancer. Part 3: metastatic disease.
Shah J; Khaksar SJ; Sooriakumaran P
Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
[TBL] [Abstract][Full Text] [Related]
10. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
11. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
13. The role of systemic cytotoxic therapy for prostate cancer.
Chang SS; Kibel AS
BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
15. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
16. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
Priolo C; Oh WK; Loda M
IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
[TBL] [Abstract][Full Text] [Related]
18. New strategies for the medical treatment of prostate cancer.
Isaacs JT
BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
[TBL] [Abstract][Full Text] [Related]
19. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
[TBL] [Abstract][Full Text] [Related]
20. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
